Intervention

Umeclidinium 62.5 mcg

ClinicalTrials.gov intervention label

Clinical trials3
Recruiting0
Common conditions1
Lead sponsors shown1

Clinical trials

3 shown
A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02731846 · 2016-06-01
WITHDRAWN
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02014480 · 2013-02-01
COMPLETED
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcgNCT01716520 · 2012-10-01
COMPLETED

Trial status mix

COMPLETED2
WITHDRAWN1

Phase mix

PHASE33

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.